No Data
Are Investors Undervaluing KPC Pharmaceuticals,Inc. (SHSE:600422) By 39%?
Announcement of KPC on the 2024 Annual Results Report
KPC Pharmaceuticals Records 46% Higher Net Attributable Profit in 2024
KPC Pharmaceuticals, Inc. (600422.SH): In 2024, Net income is expected to grow by 19.86% year-on-year.
On February 10, Gelonghui reported that KPC Pharmaceuticals, Inc. (600422.SH) announced its preliminary annual performance report for 2024. In 2024, the company will fully promote long-term stable and high-quality development and achieved good operating results, with revenue reaching 8,401.4472 million yuan, an increase of 9.07% compared to the audited figure from the previous year (before restatement), a decrease of 0.34% compared to the figure after restatement; the net income attributable to shareholders of the listed company was 648.0813 million yuan, up 45.74% from the audited figure from the previous year (before restatement), and an increase of 19.86% compared to the figure after restatement.
Private Companies Are KPC Pharmaceuticals,Inc.'s (SHSE:600422) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥462m Last Week
KPC Pharmaceuticals Secures Drug Marketing Authorization for Mycophenolate Mofetil
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing